Page 9 of 19 · 454 questions tagged vendor-vetting.
The method section is present, which is unusual enough that I want to make use of it. I have done this once and I suspect I got away with it rather than got it right.…
Setup, so nobody has to ask: QST · liraglutide. I want to know whether there is evidence behind this or only repetition. I have checked the obvious registries and…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I have the document in front of me and I can read the numbers. What I cannot…
Stated plainly: BCH · cagrilintide. This is asserted often enough that I assumed it was established, and then I went looking for the source. I have searched the…
The lot number on the vial matches the certificate, which at least rules out the easy problem. I have done this once and I suspect I got away with it rather than got…
The particulars: WXT · Shanghai Sigma-Audley. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…
What I am working with: 96.4% · cagrilintide · CPC. I am trying to build something sustainable rather than something thorough that I will abandon. I have already…
The lane and the lead time matter as much as the material for what I am doing. I would like to define my thresholds before I have a result, for obvious reasons. I…
This is my second independent submission on material from the same supplier. I understand the observation; what I do not understand is the mechanism behind it. I have…
Details up front: method section · TFC. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable…
Concretely: 98.4% · tirzepatide · BCH. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the…
Stated plainly: PeptideMeter · Qingdao Saber Technology. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern…
Stated plainly: FGP · a GLP-1 receptor agonist. This is not behaving the way I expected and I want to understand the discrepancy before I act on it. I have…
This is my second independent submission on material from the same supplier. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware…
This is my second independent submission on material from the same supplier. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware…
Conditions: date of analysis · TFC. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
The specifics, since they change the answer: tirzepatide · list of related substances. I want to understand what this actually establishes, as opposed to what it is…
Conditions: PeptideMeter · Tianjin Finder Chemical. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…
Setup, so nobody has to ask: dulaglutide · sampling plan. I have read the primary source rather than the summary, which has left me with more questions. I understand…
Conditions: method section · QST. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable with…
Details up front: SWB · Shanghai ERP Biotechnology. I have used one of these for a while and I am considering switching, which requires a reason. What I care about is…
Numbers first: 96.4% · orforglipron · QYB. This is a planning question. I know what my options are; I do not know how to weigh them. What I want is the minimum viable…
Stated plainly: SWB · Flourishglobal Peptide Biotech. I want to know what the trade-off actually is rather than which option is fashionable. I would rather have a…
What I have: method section · HJ. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable with…